Tag: U. S. FEDERAL TRADE COMMISSION

Novo Holdings has met all regulatory conditions for its $16.5 billion purchase of Catalent, which is expected to close soon. This acquisition aims to increase production of Wegovy, with Novo Nordisk having indicated potential impacts on its operating profit growth. Despite facing opposition, particularly from U.S. consumer advocates, the deal received EU antitrust approval, and…